
Tactile Systems (TCMD) Stock Forecast & Price Target
Tactile Systems (TCMD) Analyst Ratings
Bulls say
Tactile Systems Tech is poised for success in the growing market of at-home therapies for chronic conditions, with a strong revenue forecast and a focus on efficiency through process improvement and AI. With a competitive position in both basic and advanced compression markets and a patient-centered approach, the company is well-equipped for future growth and has a projected revenue of $408.5M in the next 12-24 months. Risks such as slow adoption or competition may be present, but overall the company's attractive valuation and promising outlook make it a solid investment opportunity.
Bears say
Tactile Systems Tech is benefitting from the Medicare NCD driving patient visits and indication uptake with increased flexitouch adoption outpacing nimbl. The acquisition of LymphaTech is providing a boost, bringing in additional revenue streams with its innovative solution for diagnosing and documenting lymphatic fluid. However, this bullish outlook is counterbalanced by relatively high operating expenses, as well as uncertain revenue potential from the ongoing integration and development of LymphaTech.
This aggregate rating is based on analysts' research of Tactile Systems and is not a guaranteed prediction by Public.com or investment advice.
Tactile Systems (TCMD) Analyst Forecast & Price Prediction
Start investing in Tactile Systems (TCMD)
Order type
Buy in
Order amount
Est. shares
0 shares